An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Alnylam to Webcast Presentation at 11th Annual SVB Leerink Global Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Alnylam Pharmaceuticals (Nasdaq: ALNY) will present a company overview at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 10:00 am ET. The event will be held virtually, and interested parties can access a live audio webcast through the Investors section of their website. Alnylam is renowned for pioneering RNAi therapeutics, with innovative products including ONPATTRO®, GIVLAARI®, OXLUMO®, and Leqvio®, and is committed to delivering transformative medicines for various diseases.
Positive
None.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 11th Annual SVB Leerink Global Healthcare Conference, being held virtually, on Thursday, February 17, 2022 at 10:00 am ET.
A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media)
617-682-4340
Josh Brodsky (Investors)
617-551-8276
Source: Alnylam Pharmaceuticals, Inc.
FAQ
When will Alnylam Pharmaceuticals present at the SVB Leerink Global Healthcare Conference?
Alnylam Pharmaceuticals will present at the SVB Leerink Global Healthcare Conference on February 17, 2022, at 10:00 am ET.
Where can I watch the Alnylam Pharmaceuticals presentation live?
The live audio webcast of Alnylam Pharmaceuticals' presentation will be available on their Investors section at www.alnylam.com/events.
What is the significance of Alnylam Pharmaceuticals in RNAi therapeutics?
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, developing innovative treatments based on Nobel Prize-winning science to address rare and prevalent diseases.
What products does Alnylam Pharmaceuticals currently offer?
Alnylam Pharmaceuticals offers products including ONPATTRO®, GIVLAARI®, OXLUMO®, and Leqvio®.
What strategy is Alnylam Pharmaceuticals executing for drug development?
Alnylam Pharmaceuticals is executing the 'Alnylam P5x25' strategy, focused on delivering transformative medicines for both rare and common diseases.
